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Acute kidney injury (AKI) is a common reason for hospital admission and complication ofmany inpatient procedures.The temporal
incidence of AKI and the association of AKI admissions with in-hospital mortality are a growing problem in the world today. In
this review, we discuss the epidemiology of AKI and its association with in-hospital mortality in the United States. AKI has been
growing at a rate of 14% per year since 2001. However, the in-hospital mortality associated with AKI has been on the decline starting
with 21.9% in 2001 to 9.1 in 2011, even though the number of AKI-related in-hospital deaths increased almost twofold from 147,943
to 285,768 deaths. We discuss the importance of the 71% reduction in AKI-related mortality among hospitalized patients in the
United States and draw on the discussion of whether or not this is a phenomenon of hospital billing (coding) or improvements to
the management of AKI.
1. Introduction
Acute kidney injury (AKI) is a serious condition charac-
terized by a sudden decline in kidney function, leading to
inept excretion of nitrogenous waste from the body and
deficient serum volume and electrolyte regulation. Common
life-threatening complications of AKI include volume over-
load, hyperkalemia, acidosis, and uremia [1]. Acute tubular
necrosis (ATN) caused by ischemia, exposure to nephrotoxic
agents (e.g., medications and contrast media), or sepsis is
the leading cause of AKI among hospitalized patients in
the US [2]. Patients at risk for AKI include those with
advanced age, diabetes mellitus, heart failure, liver failure,
chronic kidney disease, hypotension, and sepsis. Patients who
undergo cardiac/vascular surgery, organ transplantation, and
mechanical ventilation or who are exposed to contrastmedia,
nonsteroidal-inflammatory drugs (NSAIDs), antimicrobial
drugs, or chemotherapeutic agents commonly experience
AKI as a complicating condition [3].
According to various reports, AKI occurs in anywhere
fromfive to twenty percent of hospitalizations in theUS [4, 5].
Patients that experience AKI are at increased risk for adverse
health outcomes such as end stage renal disease (ESRD),
pulmonary complications, and cardiovascular events [6–9].
In addition, prior research has found that AKI patients
have greater odds of all-cause mortality, increased length of
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stay, and an additional hospital cost of approximately $7,500
[7, 10]. AKI severity is positively associated with patient
morbidity and mortality [11, 12].
The patient characteristics, procedures, and nephrotoxic
agents associated with increased risk of AKI are on the rise in
the United States. For example, the US population is aging
and has experienced stark increases in the incidences of
diabetes, heart failure, and sepsis over the last few decades
[13–16]. Additionally, the utilization of procedures requiring
nephrotoxic contrast media, such as cardiac catheterization,
computerized tomography scans, and peripheral angiograms,
as well as the use of antimicrobial drugs and NSAIDs, has
grown tremendously over the same time period [2, 17–22].
Since patients developingAKIwithout requiring dialysis have
an increased risk of in-hospital and long-term mortality, we
have sought to evaluate the national trends inAKI admissions
and hospital mortality [23–25].
Due to the large increase in the prevalence of risk
factors for AKI, we hypothesized that the incidence of AKI
has correspondingly increased among hospitalized patients.
Using a nationally representative sample, we determined the
incidence and associated in-hospital mortality of AKI among
hospitalized patients in the US from 2001 to 2011.
2. Methods
2.1. Study Population. We extracted discharge data from 2001
to 2011 from the Healthcare Cost and Utilization Project’s
(HCUP) National Inpatient Sample (NIS). The NIS is a
nationally representative, stratified sample of approximately
20 percent of community hospitals in the US each year. It is
the largest deidentified US all-payer inpatient database pub-
lically available for research purposes. In 2001, 986 hospitals
in 33 states contributed over 7.4 million discharge records to
the NIS. By 2011, the NIS grew to 1,049 hospitals in 46 states
and over 8 million discharge records. The committee for the
Protection of Human Subjects at Dartmouth College waived
required approval for this study as a publically available
limited dataset.
We identified cases ofAKI using the following ICD-9-CM
codes for acute renal failure: 584.5 (with tubular necrosis),
584.6 (with lesion of renal cortical necrosis), 584.7 (with
lesion of renal medullary necrosis), 584.8 (other specified
pathologic lesions in kidney), or 584.9 (unspecified).Thefinal
cohort included 18,870,662 admissions.
We used adjusted analyses to account for comorbid
conditions, age, sex, and hospital utilization practices, such as
annual median length of stay and the proportion of patients
discharged to skilled nursing facilities (SNF). Conges-
tive heart failure, pulmonary circulation disorders, periph-
eral vascular disease, hypertension, neurological disorders,
chronic pulmonary disease, diabetes without chronic com-
plications, diabetes with chronic complications, obesity, fluid
and electrolyte disorders, blood loss anemia, and deficiency
anemias were identified using NIS comorbidity indicators.
We also identified comorbid sepsis (038.x, 112.5, 112.81, 020.2,
790.7, 785.59). Specific ICD-9-CM codes used to identify







































































Figure 1: Population incidence of acute kidney injury in the United
States, 2001 to 2011.
2.2. Statistical Analysis. We calculated population incidence
rates for AKI in the US from 2001 to 2011 by dividing the
number of discharges with AKI by the US population in
each year, using estimates from the US Census Bureau [27,
28]. Incidence estimates were stratified by sex and age for
subgroup investigation. With data from 2001 as a reference,
we used multiple logistic regression models to determine
the odds of AKI and corresponding in-hospital mortality for
each year included in the study. Models were adjusted for
age, sex, race, congestive heart failure, pulmonary circulation
disorders, peripheral vascular disease, hypertension, other
neurological disorders, chronic pulmonary disease, diabetes
without chronic complications, diabetes with chronic com-
plications, obesity, fluid and electrolyte disorders, blood loss
anemia, deficiency anemias, sepsis, and cardiac catheter-
ization. Population attributable risk of in-hospital death
associated AKI was calculated to approximate the proportion
of patient deaths that could have been prevented if AKI was
avoided. All data was analyzed using Stata 11.2 (StataCorp,
College Station, TX) and weighted at the discharge level to
account for the NIS sampling scheme.
3. Results
We identified 18,870,662 hospitalizations associatedwithAKI
from 2001 to 2011. Over this period, significant differences
were observed in all AKI patient characteristics except for sex,
age, chronic pulmonary disease, and diabetes with chronic
complications. Comorbid hypertension (22.9% to 61.2%),
obesity (2.9% to 14.1%), and deficiency anemias (20.2% to
35.9%) increased themost for AKI patients from 2001 to 2011.
Complete annual characteristics for patients with AKI are
displayed in Table 1.
3.1. Acute Kidney Injury. We identified 18,870,662 hospital-
izations associated with an AKI diagnosis over the study
period. The number of cases of AKI grew from 674,845 in
2001 to 3,151,937 in 2011, an almost fivefold increase in the
incidence of AKI in the US (Figure 1). Compared to 2001,
the odds of AKI increasing per year in 2002 to 2011 were
1.18 (95% CI: 1.17–1.18) in unadjusted analyses (Table 2). After
adjustment for patient and hospital characteristics the odds
BioMed Research International 3
Table 1: Characteristics of patients with acute kidney injury in the United States, 2001 to 2011.
All years 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 𝑃 value
𝑁 18,870,662 674,845 752,472 891,353 1,125,378 1,299,289 1,522,004 1,818,011 2,236,412 2,581,314 2,817,647 3,151,937
Female (%) 47.6 47.42 47.37 48.02 47.99 47.69 47.35 47.45 47.85 47.56 47.44 47.65 0.46
Age (median) 72 72 72 72 72 72 72 72 72 71 71 71 0.72
Age (IQR) 58–81 59–81 59–81 59–81 59–81 58–81 58–81 58–81 59–82 58–81 58–81 58–82 0.72
Length of
stay (median) 6 7 7 7 7 6 6 6 6 5 5 5 <0.001
Length of
stay (IQR) 3–11 4–13 4–13 4–13 3–12 3–12 3–11 3–11 3–10 3–10 3–10 3–9 <0.001
Heart failure
(%) 22.78 23.68 23.99 24.42 25.22 25.37 24.75 23.65 21.43 21.18 21.06 22.04 <0.001
Pulmonary




8.94 6.34 7.2 6.88 6.85 6.73 7.42 8.37 9.43 9.59 9.36 10.89 <0.001
Hypertension
(%) 52.86 22.91 26.78 44.15 45.44 46.4 49.19 48.69 53.42 56.73 58.14 61.21 <0.001
Neurological




23.4 20.9 22.23 22.62 22.91 23.8 24.31 24.36 22.36 22.9 22.84 24.11 0.29
Diabetes (%) 23.72 17.12 18.6 19.18 19.56 19.36 21.17 22.71 24.15 25.65 25.97 27.26 <0.001
Diabetes with
sequelae (%) 10.94 9.55 10.86 10.61 10.17 10.32 10.83 11.23 10.75 10.53 10.41 11.57 0.28
Obesity (%) 9.26 2.94 3.9 4.17 4.37 4.89 5.96 7.35 9.8 11.09 11.26 14.08 <0.001
Anemia (%) 30.47 20.19 22.85 23.86 23.6 23.58 26.27 28.9 32.11 32.84 32.48 35.87 <0.001
Sepsis (%) 20.8 19.31 19.87 19.65 19.88 20.35 20.58 20.55 20.87 20.52 20.58 21.12 <0.001
In-hospital
mortality (%) 12.32 21.92 20.38 18.76 16.76 15.38 14.09 12.36 11.8 10.49 9.74 9.07 <0.001
Table 2: Crude and adjusted odds ratios for acute kidney injury in








Overall 1.18 (1.17–1.18) 1.14 (1.13–1.15)
Age groups
0–19 1.10 (1.07–1.14) 1.07 (1.05–1.09)
20–44 1.17 (1.16–1.19) 1.12 (1.11–1.13)
45–64 1.18 (1.17–1.19) 1.13 (1.13–1.15)
65–74 1.17 (1.16–1.18) 1.14 (1.13–1.15)
75+ 1.19 (1.18–1.19) 1.15 (1.15–1.16)
Sex
Male 1.18 (1.17–1.18) 1.14 (1.13–1.15)
Female 1.18 (1.17–1.18) 1.14 (1.13–1.15)
of AKI increasing per year in 2002 to 2011 compared to 2001
were 1.14 (95% CI: 1.13–1.15). Subgroup analyses revealed that




























Figure 2: Population incidence of acute kidney injury by sex in the
United States, 2001 to 2011.
of AKI incidence over the study period (Figure 2). Similar
patterns of AKI incidence were also found among age groups,
although the highest increase in AKI incidence was observed
among patients greater than 75 years of age (Figure 3).
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Table 3: Crude and adjusted odds ratios for mortality amongst
acute kidney injury and dialysis-requiring acute kidney injury in the
United States, 2011 compared to 2001.
Odds of mortality following AKI
Year Crude OR 95% CI Adjusted OR 95% CI
2001 Referent
2002 0.90 (0.87–0.94) 0.92 (0.88–0.97)
2003 0.82 (0.79–0.85) 0.87 (0.83–0.91)
2004 0.72 (0.69–0.75) 0.74 (0.70–0.77)
2005 0.65 (0.62–0.68) 0.65 (0.62–0.69)
2006 0.58 (0.56–0.61) 0.60 (0.58–0.63)
2007 0.50 (0.48–0.53) 0.52 (0.49–0.55)
2008 0.48 (0.46–0.50) 0.51 (0.48–0.53)
2009 0.42 (0.40–0.44) 0.45 (0.43–0.48)
2010 0.38 (0.37–0.40) 0.42 (0.40–0.44)





























Figure 3: Population incidence of acute kidney injury by age group
in the United States, 2001 to 2011.
In-hospital mortality for AKI patients decreased from
21.9% in 2001 to 9.1% in 2011. Likewise, the odds of in-
hospital mortality for AKI patients in 2011 compared to 2001
were significantly reduced (unadjusted OR 0.36, 95%CI: 0.34
to 0.37; adjusted OR 0.29, 95% CI: 0.28 to 0.30; Table 3).
Despite declining mortality estimates, the number of AKI
patients experiencing in-hospitalmortality increased twofold
over the study period, from 147,943 to 285,744. In addition,
the population attributable risk of death associated with AKI
increased from 19.2% to 35.5% from 2001 to 2011 (Table 4).
4. Discussion
With this nationally representative study of hospitalizations
in the US, we are the first to show that while AKI has
increased, hospital mortality rates for AKI have decreased
significantly from 2001 to 2011. The incidence of AKI
increased fivefold over the study period. While we found
a downward trend in the proportion of AKI patients with
hospital mortality, the raw number of deaths and attributable
population risk of death for AKI increased significantly from
Table 4: Population attributable risk of mortality associated with
acute kidney injury and dialysis-requiring acute kidney injury in the
United States, 2001 through 2011.












2001 to 2011. By 2011, AKI was present in over 35% of all in-
hospital death cases, a 16.3% increase since the beginning of
the study period. Our findings demonstrate both the clinical
and public health significance of AKI in the US, and the
immense opportunity that exists to prevent andmanage these
life-threatening complications.
Our foremost contribution is to report on the growing
incidence of AKI in the United States from 2001 to 2011 and
to demonstrate that while AKI admissions are on the rise,
hospital mortality for AKI has declined significantly. Hsu and
colleagues did not study the epidemiology of nondialysis-
requiring AKI due to concerns about the validity of ICD-
9-CM codes without the use of companion dialysis codes
to correctly identify cases [27, 29]. However, as discussed
in our limitations section, it is becoming increasingly more
common for studies to leverage AKI ICD-9-CM codes in
claims data without dialysis as a companion code [30–32].
As a result, we were able to observe a significant increase in
AKI incidence and associated in-hospital mortality among
patients in our study.
The early 2000s saw the first investigations into the
incidence of acute renal failure and associated in-hospital
mortality. These studies expressed their findings in terms of
either cases per hospitalization or intensive care unit days,
making the results difficult to interpret and generalize across
providers, as the number of admissions and length of stay
vary between hospitals [2, 11, 33]. More recent studies have
taken a more population-based approach, estimating the
population incidence of AKI to be 2,000–3,000 per million
people per year [27, 34, 35]. To date, only Hsu and colleagues
have investigated the temporal incidence of any kind of AKI
in the US (in their case, dialysis-requiring AKI (AKI-D)
specifically) [27, 36]. Our analysis now provides the most up-
to-date and comprehensive description of AKI and related
hospital mortality epidemiology in the US. The observed
increase in the incidence of AKI in our study was likely
driven by the increasing commonality of patient risk factors
for AKI in the US population, as well as the more frequent
use of procedures and medications known to cause renal
damage. However, it is important to note that the observed
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increase in the incidence of AKI may be due to improved
recognition of AKI and coding for smaller degrees of AKI.
The availability of diagnostic criteria for AKI (e.g., RIFLE)
and growing provider awareness, regarding the relationship
between serum creatinine and renal impairment, may have
led to increased rates of AKI diagnosis over the study period
[37–39]. Though unlikely, inappropriate ICD-9-CM coding
practice could also have led to increased incidence estimates.
In order to determine if the increase of AKI incidence is
true and not a consequence of increased AKI identification
through ICD-9-CM codes, we have measured AKI-D trends
over the same time period in a different study [40]. AKI-
D is more likely to be defined consistently over the years,
and it still experiences an upward trend from 2001 to 2011,
suggesting that increasing AKI incidence is not solely a result
of inappropriate ICD-9-CM coding [40].
The strengths of our study include the use of a large
nationally representative sample of hospitalizations in the US
reporting on the incidence of AKI and hospital mortality. In
addition, our use of population attributable risk of mortality
estimates allows readers to understand both the clinical and
public health significance of AKI in the US.
However, our study has several important limitations.
First, as stated previously, we utilized ICD-9-CM codes to
identify cases of AKI. Prior analyses have not utilized ICD-
9-CM codes alone to identify cases of AKI due to concerns of
validity [27, 29]. We leveraged prior research demonstrating
the high specificity (97.7%) and low sensitivity (35.4%) of
ICD-9-CM codes in identifying cases of AKI for this analysis
[29, 41]. Second, administrative billing codes are less useful
than clinical data for identifying AKI. Clinical or laboratory
data, such as serum creatinine levels, would have provided
the most accurate marker of renal impairment had they been
available [29]. Third, the NIS is a completely deidentified
dataset, making it impossible to track specific patients over
time.
Although our study establishes the significance of the
problem, additional research is needed on the drivers of dras-
tic increase of AKI incidence in the US. More research is also
needed to understand geographic and subgroup variation, as
well as which prevention andmanagement strategies result in
the greatest decline and control of AKI among hospitalized
patients.
In summary, our study demonstrates that the incidence
of AKI increased significantly in the US between 2001 and
2011. The percentage of all in-hospital deaths occurring in
combination with AKI rose by 16.3% over the study period.
AKI represents a growing clinical and public health problem
for Americans.
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